| Patent application number | Description | Published |
|---|
| 20090142349 | CD19 Antibodies And Their uses - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed. | 06-04-2009 |
| 20090162372 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE - The present invention provides anti-ED-B antibodies, antibody fragments, and antibody mimetics and such antibodies conjugated to a partner molecule, wherein the antibody or the antibody-partner molecule conjugate provides a therapeutic effect regardless of whether the ED-B-antibody or ED-B-conjugate complex is internalized within a targeted cell. | 06-25-2009 |
| 20100104509 | HUMAN ANTIBODIES THAT BIND CD19 AND USES THEREOF - Human monoclonal antibodies that specifically bind to CD19 with high affinity are disclosed The antibodies are capable of internalizing into CD19-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies are also provided Also provided are methods for detecting CD19, as well as methods for treating cancers, such as B cell malignancies, for example, non-Hodgkin's lymphoma, chronic lymphocytic leukemias, follicular lymphomas, diffuse large cell lymphomas of B lineage, and multiple myelomas using an anti-CD 19 anti-body | 04-29-2010 |
| 20100143368 | Human Antibodies That Bind Cd22 And Uses Thereof - The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure. | 06-10-2010 |
| 20110020329 | CONJUGATES OF ANTI-RG-1 ANTIBODIES - Anti-RG-1 antibodies, antibody fragments, or antibody mimetics conjugated to partner molecules, such as drugs, radioisotopes, and cytotoxins, wherein the partner molecule exerts its effect regardless of whether the RG-1 bound conjugate is internalized within a targeted cell, are useful for treating cancers. | 01-27-2011 |
| 20110085970 | ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to B7H4 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided, immunoconjugates, including antibody-drug conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer. | 04-14-2011 |
| 20120027782 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) - The present disclosure relates to antibody-partner molecule conjugates directed to PTK7. Also described are methods for treating or preventing a disease characterized by growth of tumor cells expressing PTK7 using the antibody-partner molecule conjugates. | 02-02-2012 |
